ACRS
ACRS
Last
$3.83
Day
+1.1%
1y
+94.4%
5y
-77.9%
52w
-42.6%
SPY YTD
+13.3%
Sec
—
Earnings
2026-11-0525d
EMA 21
4.75
EMA 50
5.18
EMA 200
4.53
20d high
-34.3%
5y high
-80.0%
5y range
17th
Positions held
Your positionsACRS isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-16
Hold
avoid
Signal
Strong Sell
Target
$4.62
Stop
$3.10
Stop distance
19.1%
Target vs last
+20.6%
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-15 · Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
2026-09-03 · Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
2026-09-01 · Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target
2026-08-10 · Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
2026-08-06 · Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
2026-08-06 · Aclaris: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patternsACRS · daily-32.0% over 14 sessions
Close EMA21 EMA50 EMA200